InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.42% | 13.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.42% | 13.48% | |||
| Cost of Revenue | -32.96% | 66.87% | |||
| Gross Profit | 228.42% | -61.90% | |||
| SG&A Expenses | 69.55% | -14.46% | |||
| Depreciation & Amortization | 0.96% | -1.69% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.81% | 1.78% | |||
| Operating Income | 12.92% | 4.12% | |||
| Income Before Tax | 15.68% | 17.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.68% | 17.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.68% | 17.63% | |||
| EBIT | 12.92% | 4.12% | |||
| EBITDA | 13.26% | 4.18% | |||
| EPS Basic | 38.07% | 46.90% | |||
| Normalized Basic EPS | 38.07% | 46.90% | |||
| EPS Diluted | 38.07% | 46.90% | |||
| Normalized Diluted EPS | 38.07% | 46.90% | |||
| Average Basic Shares Outstanding | 36.15% | 55.13% | |||
| Average Diluted Shares Outstanding | 36.15% | 55.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||